[
  {
    "ts": null,
    "headline": "Danaher Third-Quarter Earnings Rise; Pharma R&D Spend Expected to Rebound",
    "summary": "The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in pharmaceutical-research investment as tariff uncertainty eases.",
    "url": "https://finnhub.io/api/news?id=ddc7b2d368d3608f038c125ea497cade99a93117fd91e094a3335cd1995ffe84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761068100,
      "headline": "Danaher Third-Quarter Earnings Rise; Pharma R&D Spend Expected to Rebound",
      "id": 137181162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in pharmaceutical-research investment as tariff uncertainty eases.",
      "url": "https://finnhub.io/api/news?id=ddc7b2d368d3608f038c125ea497cade99a93117fd91e094a3335cd1995ffe84"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Growth Portfolio Drive Third-Quarter Results?",
    "summary": "Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.",
    "url": "https://finnhub.io/api/news?id=413d9b2081ab4cb54c5c4624de3ca641162dae59775f9933fd67df893d491a31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761051480,
      "headline": "Will BMY's Growth Portfolio Drive Third-Quarter Results?",
      "id": 137178115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.",
      "url": "https://finnhub.io/api/news?id=413d9b2081ab4cb54c5c4624de3ca641162dae59775f9933fd67df893d491a31"
    }
  },
  {
    "ts": null,
    "headline": "2 Mega-Dividend Stocks With Yields As High As 7%",
    "summary": "Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.",
    "url": "https://finnhub.io/api/news?id=376d5208950aa51d37f5710a2e66a1b4c1091a93ecb89fb89202e8eb95de3501",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761046620,
      "headline": "2 Mega-Dividend Stocks With Yields As High As 7%",
      "id": 137178238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.",
      "url": "https://finnhub.io/api/news?id=376d5208950aa51d37f5710a2e66a1b4c1091a93ecb89fb89202e8eb95de3501"
    }
  },
  {
    "ts": null,
    "headline": "The Play On Bristol-Myers Squibb",
    "summary": "The Play On Bristol-Myers Squibb",
    "url": "https://finnhub.io/api/news?id=e3b929cf488253a42fcf0278402ac90a1ec1fac6479996b4de42ff5f04886ce6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761046024,
      "headline": "The Play On Bristol-Myers Squibb",
      "id": 137178963,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e3b929cf488253a42fcf0278402ac90a1ec1fac6479996b4de42ff5f04886ce6"
    }
  },
  {
    "ts": null,
    "headline": "PEY: Monthly Pay And Value-Focused Portfolio",
    "summary": "PEY: Monthly Pay And Value-Focused Portfolio",
    "url": "https://finnhub.io/api/news?id=e5b1a15e33aa988be7fab16dcd6647250f1013192c7b1ce60aed46f91b14d44b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761044679,
      "headline": "PEY: Monthly Pay And Value-Focused Portfolio",
      "id": 137178621,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e5b1a15e33aa988be7fab16dcd6647250f1013192c7b1ce60aed46f91b14d44b"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Sales and Profit Rise on Bioprocessing Momentum",
    "summary": "Danaher recorded higher third-quarter sales and profit on the back of momentum in its bioprocessing business and better-than-expected sales in its respiratory market.",
    "url": "https://finnhub.io/api/news?id=6f3e381574644fead59c59d92a63e992cb808593624bf9fe413f7d70c7215164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761042180,
      "headline": "Danaher Sales and Profit Rise on Bioprocessing Momentum",
      "id": 137178239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Danaher recorded higher third-quarter sales and profit on the back of momentum in its bioprocessing business and better-than-expected sales in its respiratory market.",
      "url": "https://finnhub.io/api/news?id=6f3e381574644fead59c59d92a63e992cb808593624bf9fe413f7d70c7215164"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial",
    "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial. ​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. […]",
    "url": "https://finnhub.io/api/news?id=361f560000dd037c0974b676540981dc95a221fd751888c454b2b145919e073e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761040372,
      "headline": "Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial",
      "id": 137178240,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "​Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial. ​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. […]",
      "url": "https://finnhub.io/api/news?id=361f560000dd037c0974b676540981dc95a221fd751888c454b2b145919e073e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE): Exploring Valuation as Shares Tick Higher Despite Sector Headwinds",
    "summary": "Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand what is driving the action. Over the past month, the stock has gained about 3% despite mixed signals across the sector. See our latest analysis for Pfizer. Pfizer’s recent climb comes even as the broader sector faces some headwinds. While there’s been a modest 2.75% share price return over the past month, the longer-term picture is less rosy, with a 1-year total...",
    "url": "https://finnhub.io/api/news?id=2ff74351ed79bb368eccf1c26bb4c965c2e9a01b1d054b21dd57dc8a4e53337e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761034231,
      "headline": "Pfizer (PFE): Exploring Valuation as Shares Tick Higher Despite Sector Headwinds",
      "id": 137174420,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand what is driving the action. Over the past month, the stock has gained about 3% despite mixed signals across the sector. See our latest analysis for Pfizer. Pfizer’s recent climb comes even as the broader sector faces some headwinds. While there’s been a modest 2.75% share price return over the past month, the longer-term picture is less rosy, with a 1-year total...",
      "url": "https://finnhub.io/api/news?id=2ff74351ed79bb368eccf1c26bb4c965c2e9a01b1d054b21dd57dc8a4e53337e"
    }
  }
]